Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “We bought shares of Arcutis Biotherapeutics, Inc., which sells Zoryve for autoimmune dermatologic conditions. Zoryve offers steroid-like efficacy with fewer side effects and chronic usability. Insurance access has expanded, with 80% of commercially insured patients now covered. Approved indications target 30 million U.S. patients, and moderate adoption implies over $3 billion in peak sales. Arcutis is already free cash flow positive with 90% gross margins, positioning it for significant operating leverage. BSD Analysis: Arcutis is a dermatology-focused biotech where differentiation is driven by convenience and efficacy, not moonshot science. Topical and oral therapies target large patient populations with chronic conditions. Commercial execution now matters as much as clinical data. Investors price the equity as binary because launch success determines everything. Reimbursement and physician adoption are the gating factors. Capital needs persist until scale emerges. This is execution-heavy biotech with asymmetric outcomes.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
